CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110

Shanhu Hu, Alexey Danilov, Kristina Godek, Bernardo Orr, Laura J. Tafe, Jaime Rodriguez-Canales, Carmen Behrens, Barbara Mino, Cesar A. Moran, Vincent A. Memoli, Lisa Maria Mustachio, Fabrizio Galimberti, Saranya Ravi, Andrew De Castro, Yun Lu, David Sekula, Angeline S. Andrew, Ignacio I. Wistuba, Sarah Freemantle, Duane A. ComptonEthan Dmitrovsky

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aneuploidy is frequently detected in human cancers and is implicated in carcinogenesis. Pharmacologic targeting of aneuploidy is an attractive therapeutic strategy, as this would preferentially eliminate malignant over normal cells. We previously discovered that CDK2 inhibition causes lung cancer cells with more than two centrosomes to undergo multipolar cell division leading to apoptosis, defined as anaphase catastrophe. Cells with activating KRAS mutations were especially sensitive to CDK2 inhibition. Mechanisms of CDK2-mediated anaphase catastrophe and how activated KRAS enhances this effect were investigated. Live-cell imaging provided direct evidence that following CDK2 inhibition, lung cancer cells develop multipolar anaphase and undergo multipolar cell division with the resulting progeny apoptotic. The siRNA-mediated repression of the CDK2 target and centrosome protein CP110 induced ana-phase catastrophe of lung cancer cells. In contrast, CP110 overexpression antagonized CDK2 inhibitor-mediated anaphase catastrophe. Furthermore, activated KRAS mutations sensitized lung cancer cells to CDK2 inhibition by deregulating CP110 expression. Thus, CP110 is a critical mediator of CDK2 inhibition-driven anaphase catastrophe. Independent examination of murine and human paired normal-malignant lung tissues revealed marked upregulation of CP110 in malignant versus normal lung. Human lung cancers with KRAS mutations had significantly lower CP110 expression as compared with KRAS wild-type cancers. Thus, a direct link was found between CP110 and CDK2 inhibitor antineoplastic response. CP110 plays a mechanistic role in response of lung cancer cells to CDK2 inhibition, especially in the presence of activated KRAS mutations.

Original languageEnglish (US)
Pages (from-to)2029-2038
Number of pages10
JournalCancer Research
Volume75
Issue number10
DOIs
StatePublished - May 15 2015
Externally publishedYes

Fingerprint

Anaphase
Lung Neoplasms
Proteins
Centrosome
Mutation
Aneuploidy
Cell Division
Lung
Antineoplastic Agents
Small Interfering RNA
Neoplasms
Carcinogenesis
Up-Regulation
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hu, S., Danilov, A., Godek, K., Orr, B., Tafe, L. J., Rodriguez-Canales, J., ... Dmitrovsky, E. (2015). CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110. Cancer Research, 75(10), 2029-2038. https://doi.org/10.1158/0008-5472.CAN-14-1494

CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110. / Hu, Shanhu; Danilov, Alexey; Godek, Kristina; Orr, Bernardo; Tafe, Laura J.; Rodriguez-Canales, Jaime; Behrens, Carmen; Mino, Barbara; Moran, Cesar A.; Memoli, Vincent A.; Mustachio, Lisa Maria; Galimberti, Fabrizio; Ravi, Saranya; De Castro, Andrew; Lu, Yun; Sekula, David; Andrew, Angeline S.; Wistuba, Ignacio I.; Freemantle, Sarah; Compton, Duane A.; Dmitrovsky, Ethan.

In: Cancer Research, Vol. 75, No. 10, 15.05.2015, p. 2029-2038.

Research output: Contribution to journalArticle

Hu, S, Danilov, A, Godek, K, Orr, B, Tafe, LJ, Rodriguez-Canales, J, Behrens, C, Mino, B, Moran, CA, Memoli, VA, Mustachio, LM, Galimberti, F, Ravi, S, De Castro, A, Lu, Y, Sekula, D, Andrew, AS, Wistuba, II, Freemantle, S, Compton, DA & Dmitrovsky, E 2015, 'CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110', Cancer Research, vol. 75, no. 10, pp. 2029-2038. https://doi.org/10.1158/0008-5472.CAN-14-1494
Hu, Shanhu ; Danilov, Alexey ; Godek, Kristina ; Orr, Bernardo ; Tafe, Laura J. ; Rodriguez-Canales, Jaime ; Behrens, Carmen ; Mino, Barbara ; Moran, Cesar A. ; Memoli, Vincent A. ; Mustachio, Lisa Maria ; Galimberti, Fabrizio ; Ravi, Saranya ; De Castro, Andrew ; Lu, Yun ; Sekula, David ; Andrew, Angeline S. ; Wistuba, Ignacio I. ; Freemantle, Sarah ; Compton, Duane A. ; Dmitrovsky, Ethan. / CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110. In: Cancer Research. 2015 ; Vol. 75, No. 10. pp. 2029-2038.
@article{4c5febe57af74d01ba12870be3aebb57,
title = "CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110",
abstract = "Aneuploidy is frequently detected in human cancers and is implicated in carcinogenesis. Pharmacologic targeting of aneuploidy is an attractive therapeutic strategy, as this would preferentially eliminate malignant over normal cells. We previously discovered that CDK2 inhibition causes lung cancer cells with more than two centrosomes to undergo multipolar cell division leading to apoptosis, defined as anaphase catastrophe. Cells with activating KRAS mutations were especially sensitive to CDK2 inhibition. Mechanisms of CDK2-mediated anaphase catastrophe and how activated KRAS enhances this effect were investigated. Live-cell imaging provided direct evidence that following CDK2 inhibition, lung cancer cells develop multipolar anaphase and undergo multipolar cell division with the resulting progeny apoptotic. The siRNA-mediated repression of the CDK2 target and centrosome protein CP110 induced ana-phase catastrophe of lung cancer cells. In contrast, CP110 overexpression antagonized CDK2 inhibitor-mediated anaphase catastrophe. Furthermore, activated KRAS mutations sensitized lung cancer cells to CDK2 inhibition by deregulating CP110 expression. Thus, CP110 is a critical mediator of CDK2 inhibition-driven anaphase catastrophe. Independent examination of murine and human paired normal-malignant lung tissues revealed marked upregulation of CP110 in malignant versus normal lung. Human lung cancers with KRAS mutations had significantly lower CP110 expression as compared with KRAS wild-type cancers. Thus, a direct link was found between CP110 and CDK2 inhibitor antineoplastic response. CP110 plays a mechanistic role in response of lung cancer cells to CDK2 inhibition, especially in the presence of activated KRAS mutations.",
author = "Shanhu Hu and Alexey Danilov and Kristina Godek and Bernardo Orr and Tafe, {Laura J.} and Jaime Rodriguez-Canales and Carmen Behrens and Barbara Mino and Moran, {Cesar A.} and Memoli, {Vincent A.} and Mustachio, {Lisa Maria} and Fabrizio Galimberti and Saranya Ravi and {De Castro}, Andrew and Yun Lu and David Sekula and Andrew, {Angeline S.} and Wistuba, {Ignacio I.} and Sarah Freemantle and Compton, {Duane A.} and Ethan Dmitrovsky",
year = "2015",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-14-1494",
language = "English (US)",
volume = "75",
pages = "2029--2038",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110

AU - Hu, Shanhu

AU - Danilov, Alexey

AU - Godek, Kristina

AU - Orr, Bernardo

AU - Tafe, Laura J.

AU - Rodriguez-Canales, Jaime

AU - Behrens, Carmen

AU - Mino, Barbara

AU - Moran, Cesar A.

AU - Memoli, Vincent A.

AU - Mustachio, Lisa Maria

AU - Galimberti, Fabrizio

AU - Ravi, Saranya

AU - De Castro, Andrew

AU - Lu, Yun

AU - Sekula, David

AU - Andrew, Angeline S.

AU - Wistuba, Ignacio I.

AU - Freemantle, Sarah

AU - Compton, Duane A.

AU - Dmitrovsky, Ethan

PY - 2015/5/15

Y1 - 2015/5/15

N2 - Aneuploidy is frequently detected in human cancers and is implicated in carcinogenesis. Pharmacologic targeting of aneuploidy is an attractive therapeutic strategy, as this would preferentially eliminate malignant over normal cells. We previously discovered that CDK2 inhibition causes lung cancer cells with more than two centrosomes to undergo multipolar cell division leading to apoptosis, defined as anaphase catastrophe. Cells with activating KRAS mutations were especially sensitive to CDK2 inhibition. Mechanisms of CDK2-mediated anaphase catastrophe and how activated KRAS enhances this effect were investigated. Live-cell imaging provided direct evidence that following CDK2 inhibition, lung cancer cells develop multipolar anaphase and undergo multipolar cell division with the resulting progeny apoptotic. The siRNA-mediated repression of the CDK2 target and centrosome protein CP110 induced ana-phase catastrophe of lung cancer cells. In contrast, CP110 overexpression antagonized CDK2 inhibitor-mediated anaphase catastrophe. Furthermore, activated KRAS mutations sensitized lung cancer cells to CDK2 inhibition by deregulating CP110 expression. Thus, CP110 is a critical mediator of CDK2 inhibition-driven anaphase catastrophe. Independent examination of murine and human paired normal-malignant lung tissues revealed marked upregulation of CP110 in malignant versus normal lung. Human lung cancers with KRAS mutations had significantly lower CP110 expression as compared with KRAS wild-type cancers. Thus, a direct link was found between CP110 and CDK2 inhibitor antineoplastic response. CP110 plays a mechanistic role in response of lung cancer cells to CDK2 inhibition, especially in the presence of activated KRAS mutations.

AB - Aneuploidy is frequently detected in human cancers and is implicated in carcinogenesis. Pharmacologic targeting of aneuploidy is an attractive therapeutic strategy, as this would preferentially eliminate malignant over normal cells. We previously discovered that CDK2 inhibition causes lung cancer cells with more than two centrosomes to undergo multipolar cell division leading to apoptosis, defined as anaphase catastrophe. Cells with activating KRAS mutations were especially sensitive to CDK2 inhibition. Mechanisms of CDK2-mediated anaphase catastrophe and how activated KRAS enhances this effect were investigated. Live-cell imaging provided direct evidence that following CDK2 inhibition, lung cancer cells develop multipolar anaphase and undergo multipolar cell division with the resulting progeny apoptotic. The siRNA-mediated repression of the CDK2 target and centrosome protein CP110 induced ana-phase catastrophe of lung cancer cells. In contrast, CP110 overexpression antagonized CDK2 inhibitor-mediated anaphase catastrophe. Furthermore, activated KRAS mutations sensitized lung cancer cells to CDK2 inhibition by deregulating CP110 expression. Thus, CP110 is a critical mediator of CDK2 inhibition-driven anaphase catastrophe. Independent examination of murine and human paired normal-malignant lung tissues revealed marked upregulation of CP110 in malignant versus normal lung. Human lung cancers with KRAS mutations had significantly lower CP110 expression as compared with KRAS wild-type cancers. Thus, a direct link was found between CP110 and CDK2 inhibitor antineoplastic response. CP110 plays a mechanistic role in response of lung cancer cells to CDK2 inhibition, especially in the presence of activated KRAS mutations.

UR - http://www.scopus.com/inward/record.url?scp=84942889240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942889240&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1494

DO - 10.1158/0008-5472.CAN-14-1494

M3 - Article

C2 - 25808870

AN - SCOPUS:84942889240

VL - 75

SP - 2029

EP - 2038

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -